Investment analysts at Royal Bank Of Canada assumed coverage on shares of ObsEva SA (NASDAQ:OBSV) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “outperform” rating on the stock.

A number of other research firms have also weighed in on OBSV. Zacks Investment Research raised shares of ObsEva SA from a “sell” rating to a “hold” rating in a research note on Tuesday, May 30th. HC Wainwright set a $27.00 price objective on shares of ObsEva SA and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of ObsEva SA in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $23.25.

ObsEva SA (NASDAQ:OBSV) traded down 0.28% during midday trading on Thursday, hitting $7.05. 12,055 shares of the stock traded hands. The company’s market cap is $200.90 million. ObsEva SA has a 52-week low of $6.77 and a 52-week high of $14.18. The firm’s 50-day moving average is $6.96 and its 200-day moving average is $10.41.

ObsEva SA (NASDAQ:OBSV) last posted its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.13). During the same period in the previous year, the company posted ($0.30) EPS. Analysts predict that ObsEva SA will post ($2.32) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Royal Bank Of Canada Begins Coverage on ObsEva SA (OBSV)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-begins-coverage-on-obseva-sa-obsv.html.

A number of large investors have recently added to or reduced their stakes in the stock. Baker Avenue Asset Management LP purchased a new stake in ObsEva SA in the first quarter worth about $104,000. Paloma Partners Management Co purchased a new stake in shares of ObsEva SA during the first quarter valued at about $131,000. Sphera Funds Management LTD. lifted its position in shares of ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after buying an additional 20,411 shares during the last quarter. Iguana Healthcare Management LLC purchased a new stake in shares of ObsEva SA during the first quarter valued at about $260,000. Finally, Spark Investment Management LLC purchased a new stake in shares of ObsEva SA during the first quarter valued at about $518,000. 48.46% of the stock is owned by institutional investors.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

The Fly

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.